ReviewEuropean cardiology2025

The Use of Apabetalone in Reducing Cardiovascular Outcomes, Based on the Current Evidence and Trials.

Yimeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.